University of Kentucky

UKnowledge
Internal Medicine Faculty Publications

Internal Medicine

3-2-2017

Roadmap to a Comprehensive Clinical Data Warehouse for
Precision Medicine Applications in Oncology
David J. Foran
Rutgers University - New Brunswick

Wenjin Chen
Rutgers University - New Brunswick

Huiqi Chu
Rutgers University - New Brunswick

Evita Sadimin
Rutgers University - New Brunswick

Doreen Loh
Rutgers University - New Brunswick

See next page for additional authors
Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub
Part of the Bioinformatics Commons, and the Oncology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Foran, David J.; Chen, Wenjin; Chu, Huiqi; Sadimin, Evita; Loh, Doreen; Riedlinger, Gregory; Goodell, Lauri A.;
Ganesan, Shridar; Hirshfield, Kim; Rodriguez, Lorna; and DiPaola, Robert S., "Roadmap to a Comprehensive
Clinical Data Warehouse for Precision Medicine Applications in Oncology" (2017). Internal Medicine
Faculty Publications. 111.
https://uknowledge.uky.edu/internalmedicine_facpub/111

This Article is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been
accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of UKnowledge. For
more information, please contact UKnowledge@lsv.uky.edu.

Roadmap to a Comprehensive Clinical Data Warehouse for Precision Medicine
Applications in Oncology
Digital Object Identifier (DOI)
https://doi.org/10.1177/1176935117694349

Notes/Citation Information
Published in Cancer Informatics, v. 16, p. 1-10.
© The Author(s) 2017
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is
attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/openaccess-at-sage).

Authors
David J. Foran, Wenjin Chen, Huiqi Chu, Evita Sadimin, Doreen Loh, Gregory Riedlinger, Lauri A. Goodell,
Shridar Ganesan, Kim Hirshfield, Lorna Rodriguez, and Robert S. DiPaola

This article is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/111

694349
research-article2017

CIX0010.1177/1176935117694349Cancer InformaticsForan et al

Roadmap to a Comprehensive Clinical Data Warehouse
for Precision Medicine Applications in Oncology
David J Foran1,2, Wenjin Chen1,2, Huiqi Chu1,2, Evita Sadimin1,2,
Doreen Loh1, Gregory Riedlinger1,2, Lauri A Goodell2, Shridar
Ganesan1, Kim Hirshfield1, Lorna Rodriguez1 and Robert S DiPaola3

Cancer Informatics
Volume 16: 1–10
© The Author(s) 2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1176935117694349
https://doi.org/10.1177/1176935117694349

1Rutgers

Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New
Brunswick, NJ, USA. 2Department of Pathology and Laboratory Medicine, Rutgers Robert Wood
Johnson Medical School, New Brunswick, NJ, USA. 3College of Medicine, University of Kentucky,
Lexington, KY, USA.

ABSTRACT: Leading institutions throughout the country have established Precision Medicine programs to support personalized treatment of
patients. A cornerstone for these programs is the establishment of enterprise-wide Clinical Data Warehouses. Working shoulder-to-shoulder, a
team of physicians, systems biologists, engineers, and scientists at Rutgers Cancer Institute of New Jersey have designed, developed, and
implemented the Warehouse with information originating from data sources, including Electronic Medical Records, Clinical Trial Management
Systems, Tumor Registries, Biospecimen Repositories, Radiology and Pathology archives, and Next Generation Sequencing services. Innovative
solutions were implemented to detect and extract unstructured clinical information that was embedded in paper/text documents, including
synoptic pathology reports. Supporting important precision medicine use cases, the growing Warehouse enables physicians to systematically
mine and review the molecular, genomic, image-based, and correlated clinical information of patient tumors individually or as part of large
cohorts to identify changes and patterns that may influence treatment decisions and potential outcomes.
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Introduction

Leading health care centers across the country now recognize
the paramount importance and utility of establishing a clinical
data warehouse. In fact, some of the earliest pioneering projects
have already crossed the 20-year mark.1–5 Primary benefits that
have been realized as a result of these early efforts include cost
containment and tracking patient outcomes, providing clinical
decision support at point of care, improving prognostic accuracy, and facilitating research and clinical trials.6–8
Despite many positive reports from academic and clinical
sites across the country regarding the development of data
management and analytical tools, most centers report that the
specific solutions that were implemented have notable limitations and flaws.9The most often cited challenges are related to
the intrinsic complexity of the underlying biomedical and clinical data—the fact that information exists in both structured
and unstructured formats, and the wide range of data ownership and regulatory issues associated with collecting and organizing the data.9 To address these issues, many clinical data
warehouse projects required large up-front costs on Information
Technology (IT) implementation, which relied, chiefly, on
manual data entry. Once the data were migrated into the warehouse, there was often only limited support for performing ad
hoc queries and only minimal bioinformatics and computational tools available to enable investigators and physicians to
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systematically mine and interrogate complex genomic signatures, or to detect and track subtle changes in patient response
to therapy and treatment.
As part of our mission as a National Cancer Institute–
designated Comprehensive Cancer Center, Rutgers Cancer
Institute of New Jersey has made the goal of implementing a
clinical data warehouse a high priority to facilitate improvements in prevention, detection, treatment, and care of cancer
patients. Working shoulder-to-shoulder, a team of physicians,
systems biologists, engineers, and scientists at our Center have
designed, developed, and implemented the methods, protocols,
and workflows to facilitate the extraction, standardization, and
ongoing population of a Clinical Data Warehouse (Warehouse
in subsequent text) with information originating from a full
range of data sources, including not only the Electronic Medical
Record (EMR) system which contains patient visit records,
clinical history, physician order entries, and data originating
from laboratory results, radiology reports, and pathology reports
but also genomic sequencing studies and research-generated
data records. Our overarching efforts focus on identifying and
consolidating information most crucial to diagnosis, choices in
treatment and therapy planning, as well as investigative research.
One of the great challenges when establishing a comprehensive Warehouse lies in the fact that a vast amount

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial
4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Cancer Informatics 

2

of clinical data are found in unstructured or semistructured
format. Some of these reports are generated from outside
consultations or referring laboratories. At many institutions,
such documents are simply scanned into images or PDF and
attached to the patient record. Others may arrive via structured vehicles such as HL7 format, while the clinical content
of the message is lumped into a continuous ASCII (American
Standard Code for Information Interchange) string. These
solutions only satisfy rudimentary requirements of foundational interoperability by allowing the information to flow into
another Healthcare Information Technology (HIT) system;
however, the data cannot be easily interpreted in the destination database. To effectively incorporate this information into
the Warehouse and achieve semantic interoperability,10,11 our
team has contracted with Extract Systems (Madison, WI), a
Wisconsin-based high-tech company, to develop and optimize software that semiautomatically extracts data that would
otherwise remain locked in paper-based documents, so that
the information can be reliably uploaded into discrete fields
for integration with clinical data warehouse repository. Using
this technology, our team is able to automatically capture
more than 500 data elements, which had previously been
trapped in pathology reports and historic gene sequencing
reports. Even without human supervision, the software is
able to extract, at an accuracy rate of 96.65%, not only the
traditional pathological description of gross and microscopic pathologic findings in tumor specimen but also a full
set of discrete elements as defined in individual cancer synoptic protocols from the College of American Pathologists,12
including the most critical pathology staging information,
which is often missing from the EMR.
Whole exome sequencing and targeted exon sequencing
have become the methods of choice for identifying actionable molecular traits of a given tumor. The capacity of a
clinical data warehouse to support systematic queries facilitates the process of identifying candidates for new therapies
and providing directions for future research. In this article,
we demonstrate an automated work flow for incorporating
sequencing results from both structured and unstructured
sources.
During the course of this project our team has established
productive collaborations with several vendors, which has led
to the development of software that allows integration of radiology imaging studies and digitized pathology specimens
within the Warehouse. The colocalization of correlated data
elements, which represent the full spectrum of clinical information, imaging studies, and genomic information, coupled
with our experience and expertise in advanced pattern recognition, high-performance computing, and data mining, has
placed our team in an excellent position to optimize personalized treatment, refine best practices, and provide objective,
reproducible insight as to the underlying mechanisms of disease onset and progression.

Methods
Governance
To support the planning and development of the Warehouse,
a Data Governance Council has been established to provide
clinical insight and guide the methods used for gathering,
accessing, and sharing the data. The Council is led by a crosssection of physicians, scientists, administrators, and bioinformatics and IT staff members who work in concert in the
planning, review, and decision-making activities of the Cancer
Center. The overarching mission of the Data Governance
Council is to provide policy and oversight for all key, datacentric, clinical, and research projects at Rutgers Cancer
Institute of New Jersey. The Council is charged with establishing, reviewing, and optimizing all standing policies and
standard operating procedures for evaluating requests from
investigators for access and use of both de-identified and
Protected Health Information (PHI) data sets.
As part of its charge, the Council is responsible for (1)
providing support and training to the Rutgers Cancer community through a series of programs and workshops to support data literacy, (2) establishing a review process for
evaluating investigator-initiated project proposals, (3) reviewing and providing storage infrastructure and security, (4)
advocating for data quality and ease of access, (5) addressing
data life cycle policy issues, (6) establishing standards for
master reference data, and (7) staying abreast of the scientific,
technological, legal, and ethical standards and guidelines
related to data use and disclosure that form the basis of the
Rutgers Cancer Institute of New Jersey policies and operational decisions in addition to State, Federal, and Institutional
Review Board (IRB) protocols.

Design and components
Figure 1 shows a high-level diagram which depicts the general
work flow of the clinical data warehouse solution including:
operational databases and external data sources, Extraction
Transformation Loading (ETL) interfaces, data warehouse,
data mart, and data analysis as shown in Figure 1A. Although
the traditional approach for building such a system would
begin with extracting data from the operational databases and
external sources and then implementing an ETL to populate
the warehouse, our team recognized the large number of failed
attempts at other institutions to construct a functional system
in this manner. Although the specific details may vary, the primary design flaw of many of those projects was that the primary focus was on the extraction of information from the data
sources, before clearly identifying the use-case scenarios and
clarifying the required data mapping. Being aware of the
potential pitfalls of this approach, our team decided to implement a “backward-in” strategy for our project.
The key feature of the “backward-in” strategy is to first establish a remotely hosted data mart which is then manually
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Figure 1. Architecture of the clinical data warehouse project. (A) Key layers of the data warehouse layout. (B) Components in the implementation. The
data lake component as well as further reporting and mining tools have not yet been implemented and are therefore rendered in gray.

populated with data elements corresponding to a representative
set of cases. As part of a pilot study, our staff entered approximately 1000 such cases and then began to exercise the query, visualization, and logical tools featured by each candidate data mart.
A steering committee composed of surgical and medical oncologists worked closely with our biomedical informatics team and
IT staff to determine whether the candidate data mart provided
adequate support for the types of experiments and investigations
which are underway. During the same time, the Committee made
recommendations as to whether additional data modalities or elements should be included in the repository.
Once the Committee was satisfied with the data mart and
the data elements that it housed, our development team turned
attention toward building a fully automatic ETL. Having conducted the “backward-in” pilot study and having a solid understanding of how the data elements in the mart should be
organized, the team knew exactly which data sources, mapping
strategies, and interfaces would be required. The project then
proceeded by completing the build and then taking advantage
of the automated features of the ETL to allow prospective population of the clinical data warehouse and mart going forward.

Feeder databases and data lake
Development of a research-centric clinical data warehouse
must offer the flexibility of accommodating new projects and
protocols, which invariably presents new data requirements.
The industrial solution for such challenges has been to
establish a Hadoop-based data lake,13 which can serve as a file
reservoir to house both structured and unstructured data that
have not yet been integrated into the warehouse schema. The
data lake implementation uses a “schema-on-read” principle,
which enables and requires data specialists and data scientists
to process raw data on demand to satisfy analysis needs. As
many of our clinical data warehouse end users are typically

researchers and clinicians with limited IT experience, it was of
vital importance for us to establish simple methods for managing data requirements and our staff ’s efforts. We accomplished
this by establishing feeder databases.
Feeder databases are efforts led by research scientists to
establish prototypical relational databases of specific subject
areas that can subsequently be forwarded to data marts for
integration. Our current feeder databases include data elements derived from complete synoptic pathology reports as
well as complete itemized variant report data from exon
sequencing studies, whereas the Warehouse focuses on more
refined and common data elements that apply to a wider number of projects and disease groups.
Moving data directly from feeder databases to data marts
guarantees that the corresponding data tables have the same
level of security as all the data in the Warehouse. More importantly, these data marts provide the opportunity for end users to
consume and evaluate data from subspecialty areas ahead of
Warehouse development, allowing feedback to the development team to facilitate the optimized design and ETL of the
warehouse. The feeder databases allow continued execution of
the “backward-in” strategy during ongoing development of the
Warehouse.

Data mart and security
Among the software solutions offered by the company
BioFortis, Inc. (Columbia, MD), is Labmatrix, which gained
early adoption and recognition among prestigious institutions
such as the National Human Genome Research Institute and
the National Cancer Institute, and has since become a leading
provider of information management solutions for the translational life science research community. The Qiagram software module supplements these capabilities with intuitive,
user-friendly graphical query–building capabilities. We
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adopted a combination of these software models as our data
mart solution, which established a unique, secure, and scalable
scientific intelligent environment that enables our researchers
to aggregate, explore, and interrogate information as it is collected. The BioFortis solution was designed to be subject-centric and has strong built-in capability to selectively display
identified or de-identified query results to users according to
their access privileges to specific IRB-approved research protocols. Users can either manipulate specific prebuilt reports for
their desired output or work with honest brokers to build
complicated ad hoc output of results. The graphical presentations of the queries clearly represent their logical formation
and are exceptional tools which foster brainstorming among
scientific and technical members of the team.
As approved by the IRB committee at Rutgers Cancer
Institute of New Jersey, the precision medicine honest broker
system14 is in place to help researchers use the infrastructure
provided by the Warehouse (Rutgers Cancer Institute of New
Jersey IRB protocols 0220100249, 2012002075, 0220090048,
and 0220044862). The Data Governance Council has designated Honest Broker Administrators to review all data requests
and associated IRB protocols prior to undertaking any new
study. The retrieval can either exclude all patient identifying
information or include limited data PHI elements as specified
by the study IRB. Delivery of the information can be arranged
in combination of several forms, including (1) 1-time data
download, (2) limited-access data mart browsing capability
including allowed data elements, (3) limited-time hypothesisgenerating query capability over specified data points, and (4)
live, online reports that can be filtered and aggregated by user.

Extracting discrete data from unstructured and
paper forms
The necessity to integrate data originating from disparate EMR
systems often makes it useful to store text or scanned paper
reports in their entirety for subsequent access by the physicians
and other clinical personnel. Although comprehensible by
human readers, patients’ medical information embedded in these
reports is not easily integrated into clinical databases, without
enlisting advanced optical character recognition and text-based
analytical technologies. Our team partnered with Extract
Systems to implement the software and systems to automate the
process of detecting and extracting unstructured clinical information that was embedded in paper or text documents such as
pathology reports and genomic sequencing reports.
Synoptic cancer reporting12,15,16 and pathology staging17 are
critical for producing accurate and complete cancer pathology
reporting and supporting collaboration among clinicians for the
optimal management of cancer patients. Although synoptic
reporting has already been implemented in most Laboratory
Information Systems (LIS), the EMR typically receives a full text
report via version 2 HL7 protocol.18–20 By developing a set of
universal rules based on CAP’s synoptic protocol with

implementation details provided by the Department of Pathology
and Laboratory Medicine, Robert Wood Johnson University
Hospital, the approach that we implemented is able to reliably
process the entire ensemble of information of each pathology
report into discrete data elements and output them in a corresponding structured XML format that subsequently transformed
into compatible data structure for the data warehouse. The
Warehouse is therefore capable of supporting queries into every
synoptic data element of the reports including but not limited to
margin details, lymph node findings, and additional pathological
findings. To date, our team has implemented rules for processing
synoptic reports of breast, prostate, melanoma, colon, rectum,
neuroendocrine tumor, and pancreas exocrine and pancreas endocrine tumors and plans to incorporate other tumor forms in near
future. The rules can also be easily adapted to any future changes
into the synoptic reporting scheme and be fully compatible with
implementations in other hospitals and LIS systems.
Although genomic sequencing entities such as Foundation
Medicine (Cambridge, MA) are capable of reporting in XML
formats, many users still receive emailed or faxed reports from
referring physicians and patients in PDF. The Extract Systems
implementation is also proficient in extracting genomic alterations, significant negative mutations, and variants of unknown
significance (VUS) from these reports into discrete form and
allows cataloging of the information into databases.

Image archive
One of the data types most often overlooked when building a
clinical data warehouse are medical images,21 which play a
key role in cancer diagnosis and prognosis. As medical imaging data are heterogeneous and large, they take additional
architectural layout, multiple software interfaces, and careful
security planning to allow users to retrieve and display of this
visual information.
Pathology specimens relevant to the precision medicine project as well as a range of other research protocols were imaged
at the Imaging Shared Resource at Rutgers Cancer Institute
of New Jersey. An Olympus VS120 scanner (Olympus
Corporation, Center Valley, PA) is capable of digitizing slides
with maximum magnification of 40× and throughput of 100
slides per load. The resulted images were transferred to an
online database. Each whole slide image in itself does not contain patient identifier, and they require privileged information
to be linked to research protocol and patient record. For example, pathology images were linked through pathology data types
in the schema. Users can simply click on a URL from the data
mart at which point a Web viewer interface provides access to
the corresponding whole slide images for that case. The interface supports visualization and navigation about the imaged
specimen. Radiology images were previously transmitted from
the Picture Archiving and Communication Systems (PACS)
located in the Department of Radiology at Robert Wood
Johnson University Hospital using standard transfer protocols.

Foran et al
Each image record referenced in the clinical data warehouse
is linked to the actual imaging data using URL into a Web
image archive application, which supports user viewing and
manipulation. The Web image archive applications supporting
this access satisfy the following requirements:
1. The application should support proper visualization of
the images via a Web browser. There are different
requirements for displaying each type of medical images.
Efficient traversing of whole slide images requires panning and zooming. Stack support is essential for browsing computed tomographic images.
2. Each image can be accessed via a direct URL. The application does not require user to search for a patient or
time stamp to reach the desired image.
3. The URLs can be automatically retrieved from the application’s back-end database into the clinical database with
complementary image metadata.
4. Image access is restricted based on user account and
password. Therefore, if an URL is copied and sent to
another physician, the recipient still needs his or her own
proper privilege for access.
5. The application server is strategically configured for network security at the institution.
6. If some users do not have access to PHI, the image
access is also stripped of protected information. This
may demand PHI-free version of images to be served
and/or a separate, PHI-free image server configuration
to be established.

Document archive
The data warehouse ETL process closely integrates with the
extraction workflows of unstructured information and tracks
the storage of the source data files. The Warehouse maintains a
reservoir of copies to the original pathologic report or genomic
sequencing report so that user have the capability to easily call
back, interrogate, and even reprocess these unstructured data,
should more advanced processing algorithms are developed to
understand such data. Similar to the images, these links can be
invoked interactively through the BioFortis data mart, and
through downstream applications.

Targeted exon sequencing
Rutgers Cancer Institute of New Jersey has arranged with
Foundation Medicine and RUCDR Infinite Biologics
(Piscataway, NJ) to receive a full complement of discrete data
elements for targeted exon sequencing studies performed at
their facilities. Annotated clinical summary reports in PDF as
well as the corresponding data-rich XML reports are transferred, regularly, from these services through secure network
connections and, with help of well-defined structure schema
files, are extracted, transformed, and loaded into a prototype
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feeder database of the Warehouse with an interface developed
using Informatica (Redwood City, CA) software. The resulting feeder database includes the variants with clinical significance, VUS, copy number gains and losses, gene rearrangement
- all with clinical annotation as well as details on sequencing
depth, allele frequency and sample purity measures. Gene
names in the variants data set were mapped to latest Human
Genome Organization (HUGO) gene names and indexes
published by the HUGO Gene Nomenclature Committee
(HGNC) (http://genenames.org).
A separately maintained data server is used to store exome
sequencing data files transmitted from the sequencing services.
The Warehouse maintains links to these files so that researchers, with proper permission, can access the server, directly, to
retrieve these files in spite of their large size.

Results

The oncology clinical data warehouse project was built under
the overall umbrella of the precision medicine initiative at the
Rutgers Cancer Institute of New Jersey; therefore, the key use
cases presented in this article are tightly tied to providing data
support and propelling advances in clinical applications and
investigative oncology research. The Molecular Tumor Board,
among other programs under the initiative, as well as the
Oncology Research Information Exchange Network (ORIEN)
project provided much of the motivation that inspired and
benchmarked our progress.

Institutional Molecular Tumor Board
The precision medicine programs and clinical services which
are currently underway at Rutgers Cancer Institute of New
Jersey required the establishment of a weekly Molecular Tumor
Board to enable physicians to discuss challenging clinical cancer cases for which clinical-grade tumor sequencing data have
been obtained. Patients presented at the Tumor Board have
had clinical-grade sequencing of their tumor specimens
obtained either in the context of a tumor sequencing protocol
at Rutgers Cancer Institute of New Jersey or have had tumor
sequencing performed at as part of their routine clinical care.
Patients with rare histology cancers or with tumor refractory to
standard treatment are prioritized for review. The Board is
composed of a full range of expert clinicians, including medical
oncologists, radiation therapists, surgeons, pathologists as well
as basic scientists, systems biologists and bioinformatics scientists, clinical geneticists, representatives from our early phase
clinical trials group, and experts in biomedical ethics.
At presentation, the sequencing data are reviewed in
depth by a team of physician-scientists with experience in
genomic analysis and cancer biology. The biological and
clinical relevance of potential driver mutations are identified, and potential targeted treatment strategies are raised. A
discussion regarding targeted therapies is held for each case,
and a consensus reached regarding possible therapeutic
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options. Recommendations often include referral to appropriate clinical trials, potential use of off-label therapies
when clinical trials are not available, and guidance regarding
further diagnostic interventions. A letter summarizing the
discussion is sent to the referring clinician for each case.
Follow-up clinical information and outcome data are gathered on each case where available. The Rutgers Cancer
Institute Tumor Board is routinely broadcast as interactive
sessions with investigators located at collaborating
Institutions using Health Insurance Portability and
Accountability Act–approved procedures and protocols.22–24
The Warehouse has been designed to allow capture of the
clinically salient data elements generated during the course
of this process, including but not limited to patient demographics, family history, diagnosis, treatment, pathology
report and staging, lab tests results, as well as genomic variations generated from paneled gene sequencing, to allow
subsequent viewing, mining, and analysis by the clinical and
research community.

Oncology Research Information Exchange Network
As a logical extension of the Warehouse and precision medicine activities which are being conducted, our institution has
recently become a participating member of the Oncology
Research Information Exchange Network (ORIEN). ORIEN
is a national alliance, which was formed to enable investigators
from leading institutions across the country to share “big data”
for cancer research. The Network was established in 2014 by
founding members Moffitt Cancer Center, Ohio State
University Comprehensive Cancer Center, Arthur G. James
Cancer Hospital, and Richard J. Solove Research Institute in
Columbus. ORIEN members use a standardized protocol to
follow patients throughout their lifetime (ie, Total Cancer
Care Protocol) and share both clinical and molecular data
from patients enrolled in the protocol to enhance discovery
and create evidence of what is the most effective therapy for
individual patients. In addition to the founding institutions,
ORIEN members as of today include City of Hope Cancer
Center, University of Virginia Cancer Center, University of
Colorado Cancer Center, University of New Mexico Cancer
Center, Morehouse School of Medicine, Rutgers Cancer
Institute of New Jersey, University of Southern California
Norris Cancer Center, and many more (http://oriencancer.
org/#members-list). Our team at Rutgers will leverage the
data collected through ORIEN to facilitate systematic investigations, which are focused on rare malignances for which any
one institution is unable to acquire sufficient number of cases
for rigorous statistical analysis.
The IT challenges of generating cohort patient data for the
ORIEN project were in perfect alignment with our efforts
directed toward developing the clinical data warehouse, with
many of the data elements of interest overlapping, especially
as they relate to patient diagnosis, mortality, treatment, and

biospecimens. In this use case, information from source systems—EMR, cancer registry, biospecimen banking system,
and molecular testing results—was integrated, de-identified,
and transformed in accordance to the Observational Medical
Outcomes Partnership (OMOP) data model25 so they could
be transmitted and cataloged in the ORIEN central reservoir.

Example precision medicine use case
With the help of BioFortis technology, the data marts can host
project-specific patient data to suit various needs of data access
with user-based access control. Sophisticated queries can be
built to execute complicated scientific logic and retrieve specific data sets.
Although BioFortis queries can be constructed to suit a
wide variety of specific data requirement, user can also leverage on BioFortis’s reporting capability to access data without
immediate programming help. These data reports are based
on prebuilt queries to suit general needs of the users. The
data reports can easily incorporate filters to help user tailor
the retrieval list. Figure 2 depicts an example where patient
cohort was assembled with specific gene mutation and tumor
diagnosis and treated with therapeutic agents. Users with
appropriate IRB clearance are able to access additional information for a given data set, including the capacity to access
and interrogate imaged pathology specimens. More advanced
users can receive training to build ad hoc queries into their
data mart or work closely with honest brokers to bring scientific logic to actual data.

Tissue microarray use case
Tissue microarray (TMA) technology26,27 is a cohort research
tool for assessing tumor morphology and protein marker
expression. Researchers often make discoveries by correlating
TMA results with clinical information. Although some information was collected when each TMA was constructed, it was
usually limited in comparison with what a comprehensive clinical data warehouse could offer. Therefore, as one of the first
use cases to exercise our clinical data warehouse, as well as the
first requests into the honest broker system, a research prostate
cancer TMA, which was previously constructed by our cancer
center’s BioSpecimen Repository Service and Histopathology
Shared Resources, with no clinical data other than diagnosis of
record (prostate adenocarcinoma) and Gleason score, was
revisited by the team.
Adhering to policies of the honest broker system, researchers obtained new IRB approvals to collect further information
on the TMA from the Office of Human Research Services
before submitting data collection requests to honest broker
administrators, which clearly described the project as well as
the clinical information that was desired. Clinical members of
the original research protocol inspected and quality-assured a
subset (10%) of the clinical information before the data were
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Figure 2. Example of using BioFortis Qiagram interface to formulate and execute precision medicine queries. (A) Query building diagram using Qiagram
(simplified for display purposes). (B) The result report can be published for general user access. The report form allows drop-down menu selection for
close examination according to individual interests. The example shows a cohort of lung cancer patients presenting with EGFR (Epidermal Growth Factor
Receptor) mutation who have been treated with therapeutic agents.

made available in the Warehouse. The honest broker administrator mediated further communications between the user and
the honest broker so that the honest broker can work with the
data warehouse administrator to reidentify the patients
included in the TMA, build specific queries into the data warehouse, and produce data worksheets as requested. After being
inspected by the honest broker administrator, the final data set
released to researchers included, with reference to location on
the TMA block, de-identified clinical information, including

demographics (without PHI), biopsy pathology result, prostatectomy pathology result, Gleason grading, pathology and
clinical staging, patient visit information, medical treatment,
selected pre- and postsurgical lab tests, as well as links to each
patient’s tumor whole slide images. In addition, the honest
broker built query to identify patients with biochemical
recurrence defined as 1) two consecutive prostate-specific
antigen tests after surgery with increasing result levels and 2)
the final result being over 0.2 ng/mL.
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Integrating pathology reports and scanned
sequencing reports
Each pathology report enters in our EMR system in HL7 format and is subsequently incorporated into EMRs of corresponding patients in textual/ASCII format. When displayed to
EMR users, these reports show proper alignment for optimal
human comprehension. Feeding these reports into data warehouse, however, requires well-defined data elements to be
properly recognized and extracted.
Our team worked closely with pathologists at Rutgers
Robert Wood John University Hospital and data expert at
Extract Systems to define data elements to be extracted from
pathology reports and synoptic cancer reports. In general, surgical pathology reports include a final diagnosis text, entered as
sentences or paragraphs of free texts with lack of standardized
vocabularies among pathologists; gross and microscopic
description of the specimen received and final pathologic diagnosis on each part of submitted surgical specimen; immunohistochemistry and special stains results; along with addendums
and amendments. A surgical pathology report may also include
1 or more synoptic reports, each correspond to 1 lesion in the
surgical specimen. The College for American Pathologists had
recommendations for clear and consistent reporting of tumorous lesions in the synoptic reports; therefore, the set of data
elements was well defined both medically and semantically to
be extracted into a Warehouse, with limited free texts. One
caveat is that these synoptic reports are consistently updated, at
times with differences in staging between different versions. In
many cases, pathology report included result of molecular studies, which, because it is a young and growing field, the reports
are generally more standardized, allowing for straightforward
extraction. The CoPath implementation (Cerner Corporation,
Kansas City, MO) used in Robert Wood Johnson University
Hospital closely adhered to the guidelines so that our system
can be easily generalized to other hospitals and institutions.
In an assessment of Extract Systems implementation, a balanced set of surgical pathology reports, including approximately 20 synoptic reports of each recognized type, a small set
of reports of other synoptic forms, as well as faxed and/or
scanned Foundation Medicine sequencing reports, was submitted for automatic data extraction based on rules established
at the Extract Systems software. Trained personnel used the
provided quality-control interface to examine each extracted
data element. The quality-control interface was specifically
designed for showing all extracted data elements in a userfriendly electronic form, with the original report displayed side
by side for review as shown in Figure 3. As the quality-control
personnel hit the Tab key to traverse through each data element in the form, the corresponding text from the original
report, where extraction of the very element originated, was
highlighted. If the extraction is not accurate, user can overwrite
the element, or, more easily, use the software tool to swipe the
correct area of the original report to re-extract the data. Text

highlighting is most often in green color, signaling high confidence of the detection. Occasionally, orange highlights appear
when further attention is required from the human operator in
case when the recognition and extraction may be ambiguous to
the algorithm. We found this display of confidence interval
highly useful to achieve efficiency and maintain operator’s
attention during the quality-control process.
Through Extract Systems platforms’ built-in quality monitoring functionality, we tracked the generation and quality-control
process of a total of 18 530 data elements, which originated from
26 genetic analysis reports and 212 pathology reports, including
164 synoptic tumor forms. For performance evaluation of the
Extract Systems algorithms, we considered the quality-controlled
data to be accurate, and any data field that was touched up, corrected, or added/deleted by human operators in the quality-control process was captured error. As a result, the overall accuracy of
automatic data element extraction by Extract Systems platform
was determined to be 96.65%. Of course, the actual data extraction work flow included a quality-control team that corrects any
errors that may have been introduced during the recognition process and ensures quality of the resulting data set.

Discussion and Conclusion

During the course of constructing, developing, and exercising
the oncology data warehouse, 1 key challenge that was regularly confronted was how to maintain a balance between keeping the database concise and focused, versus providing views of
the data that offer a comprehensive summary of the salient
clinical information. Although the most common usage of the
Warehouse pertains to querying to identify specific patient
cohorts with an emphasis on positive diagnostic tests (eg,
pathology synoptic) and summarized data (such as cancer-specific diagnoses, annotated genetic variations, and therapeutic
outcomes), our team also contended with demands from our
researchers to support big data mining research, which often
required thorough and temporal assembly of patient visits,
lab tests, low-level sequencing reads in the form of Binary
Alignment/Map (BAM) files, or variation calling files.
Reflecting on our strategy of implementing the “backwardin” strategy to develop the Warehouse, we recognize that it
offered many merits, including drawing quick successes to gain
wider support from management and clinical users, prioritizing the ETL on the most essential components of clinical data,
as well as allowing us to lay out and exercise the Warehouse in
parallel to the development of use-case–based applications.
This strategy of building out the Warehouse framework based
on key use cases, if not carefully implemented, could potentially
lead to a limited ETL that will not support the addition of new
use cases, and hence reduce usability of the Warehouse going
forward. The success of this project leveraged the expert knowledge and guidance provided by our Data Governance Council
through continuous communication, regular brainstorming
sessions, and iterative prototyping. Another unique effort to
ensure long-term success of the Warehouse was the parallel
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Figure 3. An example of pathology report data extraction using Extract Systems software. (A) After the software performs automatic data detection and
extraction, the verification software interface displays the report-in-process on right-hand side of screen, to be compared with the extracted information on
dynamically generated data form on the left side. Screen capture shows an example section containing part of a synoptic pathology report. Please note
one selected data element (in green) with its highlighted counterpart on the original report for easy verification. (B) Corresponding section of the resulting
XML output file was subsequently loaded into the Warehouse.

development of the feeder databases to prototype and evaluate
data types and modalities as candidate expansions to the core
Warehouse schema. Other possible technical extensions of the
Warehouse include expansion of the data elements collected
and implementation of natural language processing modules to
allow automated processing of clinical free text to incorporate
searchable information, integration of image analysis modules
to support generation and indexing of image-based features to
support content-based image retrieval and computer-aided

detection, as well as online processing and visualization tools
for genetic data.
A clinical data warehouse is composed of many components; most of them run on commercial software systems.
When selecting private vendors for each component, the
team at Rutgers Cancer Institute of New Jersey emphasized
not only on their experience in related fields but also on the
flexibility of their products in accommodating data and applications suitable for the Warehouse project. The vendors’
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cooperation provided a substantial boost to the continued
progress of the project.
A wide range of clinical data warehouse solutions are being
developed and evaluated at leading institutions across the
country to support the steady rise in the number of Precision
Medicine and Translational programs that are being established. The success of establishing a comprehensive clinical
data warehouse at our Institution in which we have included
pathology, genetics, and imaging data in a relatively short time
in Rutgers Cancer Institute of New Jersey is attributed to careful planning and governance from institute executives, close
collaboration with key clinical and operational departments,
careful selection of software partners, as well as excellent communication and orchestration from the development and
research team. The colocalization of such a broad number of
correlated data elements representing the full spectrum of clinical information, imaging studies, and genomic information
coupled with our experience and expertise in advanced pattern
recognition, high-performance computing, and data mining
has positioned our team with unique opportunities to optimize
personalizing treatment, refining best practices, and providing
objective, reproducible insight as to the underlying mechanisms of disease onset and progression.

Acknowledgements

We thank the patients and appreciate services provided by the
Biospecimen Repository Service and the Office for Human
Research Service at Rutgers Cancer Institute of New Jersey.

Author Contributions

DJF contributed in overall design, concept, and oversight. WC
and DJF wrote and edited the manuscript. HC and ES contributed to the writing of the manuscript. DL and HC
designed and implemented core warehouse, WC designed
feeder databases and developed ETL for pathology reports
and sequencing reports, WC and HC incorporated imaging
components. LR, DJF, WC, and DL established and exercised
the honest broker system. RSD and LR managed administrative and clinical adoption. SG, KH, LAG, ES, and GR contributed in data elements selection and clinical evaluation.

Disclosures and Ethics

The authors have read and confirmed their agreement with the
ICMJE authorship and conflict of interest criteria. The authors
have also confirmed that this article is unique and not under consideration or published in any other publication, and that they
have permission from rights holders to reproduce any copyrighted
material. The authors have no affiliations with, nor has any financial or nonfinancial interest with, the private vendors (Informatica,
BioFortis, and Extract Systems) mentioned in this manuscript.

References
1.

2.
3.
4.
5.
6.

7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.

23.

24.
25.
26.
27.

Winkler SJ, Witte E, Bierer BE. The Harvard catalyst common reciprocal IRB
reliance agreement: an innovative approach to multisite IRB review and oversight. Clin Transl Sci. 2015;8:57–66.
Weber GM, Murphy SN, McMurry AJ, et al. The Shared Health Research
Information Network (SHRINE): a prototype federated query tool for clinical
data repositories. J Am Med Inform Assoc. 2009;16:624–630.
Chute CG, Beck SA, Fisk TB, Mohr DN. The enterprise data trust at Mayo
Clinic: a semantically integrated warehouse of biomedical data. J Am Med Inform
Assoc. 2010;17:131–135.
Evans RS, Lloyd JF, Pierce LA. Clinical use of an enterprise data warehouse.
AMIA Annu Symp Proc. 2012;2012:189–198.
Hollis J. Deploying an HMO’s data warehouse. Health Manag Technol.
1998;19:46–48.
Zhang Q , Matsumura Y, Teratani T, et al. The application of an institutional
clinical data warehouse to the assessment of adverse drug reactions (ADRs).
Evaluation of aminoglycoside and cephalosporin associated nephrotoxicity.
Methods Inf Med. 2007;46:516–522.
Cho IS, Haug PJ. The contribution of nursing data to the development of a predictive model for the detection of acute pancreatitis. Stud Health Technol Inform.
2006;122:139–142.
Evans RS, Lloyd JF, Pierce LA. Clinical use of an enterprise data warehouse.
Paper presented at: AMIA Annual Symposium Proceedings November 3–7,
2012; Chicago, IL.
MacKenzie SL, Wyatt MC, Schuff R, Tenenbaum JD, Anderson N. Practices
and perspectives on building integrated data repositories: results from a 2010
CTSA survey. J Am Med Inform Assoc. 2012;19:e119–e124.
Blobel BG, Engel K, Pharow P. Semantic interoperability—HL7 Version 3 compared to advanced architecture standards. Methods Inf Med. 2006;45:343–353.
Dolin RH, Alschuler L. Approaching semantic interoperability in Health Level
Seven. J Am Med Inform Assoc. 2011;18:99–103.
Srigley JR, McGowan T, Maclean A, et al. Standardized synoptic cancer pathology reporting: a population-based approach. J Surg Oncol. 2009;99:517–524.
O’Leary DE. Embedding AI and crowdsourcing in the big data lake. IEEE Intell
Syst. 2014;29:70–73.
Boyd AD, Hosner C, Hunscher DA, Athey BD, Clauw DJ, Green LA. An
“Honest Broker” mechanism to maintain privacy for patient care and academic
medical research. Int J Med Inform. 2007;76:407–411.
Markel SF, Hirsch SD. Synoptic surgical pathology reporting. Hum Pathol.
1991;22:807–810.
Gill AJ, Johns AL, Eckstein R, et al. Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology. 2009;41:
161–167.
Edge S, Byrd D, Compton C, Green F, Trotti A. AJCC Cancer Staging Manual.
7th ed. New York, NY: Springer; 2010.
Dolin RH, Alschuler L, Beebe C, et al. The HL7 clinical document architecture.
J Am Med Inform Assoc. 2001;8:552–569.
Dolin RH, Alschuler L, Boyer S, et al. HL7 clinical document architecture, release 2. J Am Med Inform Assoc. 2006;13:30–39.
Beeler GW. HL7 version 3—an object-oriented methodology for collaborative
standards development. Int J Med Inform. 1998;48:151–161.
Anderson NR, Lee ES, Brockenbrough JS, et al. Issues in biomedical research
data management and analysis: needs and barriers. J Am Med Inform Assoc.
2007;14:478–488.
Bhagavathi S, Goodell L, Chan C, et al. Validation of a droplet PCR-based assay
for the detection of somatic variants in solid tumors. Paper presented at:
Association for Molecular Pathology (AMP) 2015 Annual Meeting; 2015
November 5–7; Austin, TX.
Hirshfield KM, Tolkunov D, Zhong H, et al. Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers
[published online ahead of print August 26, 2016]. Oncologist. doi:10.1634/
theoncologist.2016-0049.
Rodriguez-Rodriguez L, Hirshfield KM, Rojas V, et al. Use of comprehensive
genomic profiling to direct point-of-care management of patients with gynecologic cancers. Gynecol Oncol. 2016;141:2–9.
Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a
common data model for active safety surveillance research. J Am Med Inform
Assoc. 2012;19:54–60.
Kallioniemi O-P, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet.
2001;10:657–662.
Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med. 1998;
4:844–847.

